(secondQuint)Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases.

 This is an single-center, open-label, dose-escalating study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of single and multiple subcutaneous injection TK006 in patients with breast cancer-related bone metastases.

 It contains 4 cohorts:60 mg single-dose conhort, 120 mg single-dose conhort, 180 mg single-dose conhort and 120 mg Q4W (one dose every 4 weeks, 3 dose totally) conhort.

.

 Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases@highlight

This is a single-center, open-label, dose-escalating study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of single and multiple subcutaneous injection TK006 in patients with breast cancer-related bone metastases.

